Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We read with great interest the recent article by Borne et al.1 The researchers should be congratulated for having provided a detailed review on implantable cardioverter-defibrillator (ICD) therapies and their effects on health outcomes and strategies to reduce these therapies. The adverse prognostic value of ICD therapies (shocks and antitachycardia pacing) in a primary prevention population has been well proven in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). However the implications of ICD shocks in a secondary prevention population is unclear.
Rathod A, Badheka A, Deshmukh A. Impact of Implantable Cardioverter-Defibrillator Therapy on a Secondary Prevention Population. JAMA Intern Med. 2013;173(22):2093-2094. doi:10.1001/jamainternmed.2013.10402